{"meta":{"totalResults":4,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"oxaliplatin-folinic acid-fluorouracil regimen"},{"type":"Synonym","name":"fluorouracil/leucovorin/oxaliplatin regimen"}],"definition":{"html":"A chemotherapy regimen that includes leucovorin, 5-fluorouracil and oxaliplatin, which may be used in the treatment of pancreatic cancer.","text":"A chemotherapy regimen that includes leucovorin, 5-fluorouracil and oxaliplatin, which may be used in the treatment of pancreatic cancer."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/OFF","text":"OFF"},"nciConceptId":"C114101","nciConceptName":"OFF Regimen","termId":758533,"name":"OFF regimen","firstLetter":"o","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"off-regimen"},{"aliases":[{"type":"USBrandName","name":"Eloxatin"},{"type":"Abbreviation","name":"L-OHP"},{"type":"Abbreviation","name":"1-OHP"},{"type":"ForeignBrandName","name":"Dacotin"},{"type":"ForeignBrandName","name":"Dacplat"},{"type":"Synonym","name":"diaminocyclohexane oxalatoplatinum"},{"type":"ForeignBrandName","name":"Eloxatine"},{"type":"CodeName","name":"JM-83"},{"type":"Synonym","name":"oxalatoplatin"},{"type":"Synonym","name":"oxalatoplatinum"},{"type":"Synonym","name":"oxaliplatine"},{"type":"CodeName","name":"RP-54780"},{"type":"CodeName","name":"SR-96669"},{"type":"ChemicalStructureName","name":"[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum"},{"type":"ChemicalStructureName","name":"[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"},{"type":"ChemicalStructureName","name":"oxalato (1R,2R-cyclohexanediamine)platinum(II)"},{"type":"ChemicalStructureName","name":"oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)"},{"type":"ChemicalStructureName","name":"trans-l DACH oxalatoplatinum"},{"type":"ChemicalStructureName","name":"trans-l diaminocyclohexane oxalatoplatinum"},{"type":"Synonym","name":"Aiheng"},{"type":"Synonym","name":"Ai Heng"},{"type":"INDCode","name":"57004"},{"type":"NSCNumber","name":"266046"},{"type":"CASRegistryName","name":"63121-00-6"}],"definition":{"html":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance.","text":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/oxaliplatin","text":"Oxaliplatin"},"nciConceptId":"C1181","nciConceptName":"Oxaliplatin","termId":42374,"name":"oxaliplatin","firstLetter":"o","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"oxaliplatin"},{"aliases":[{"type":"Synonym","name":"drug-eluting beads with oxaliplatin"},{"type":"Synonym","name":"deboxa"},{"type":"Synonym","name":"CalliSpheres drug-eluting beads with oxaliplatin"},{"type":"Synonym","name":"DEB with oxaliplatin"}],"definition":{"html":"A formulation of drug-eluting beads (DEB) consisting of polymeric microbeads impregnated with the organoplatinum complex and alkylating agent oxaliplatin, with potential antineoplastic activity. The beads consist of polyvinyl alcohol (PVA) microspheres modified with sulfonic acid groups and loaded with oxaliplatin. During transarterial chemoembolization (TACE) in the hepatic artery, the oxaliplatin eluting beads occlude tumor blood vessels that feed the tumor and induce ischemic necrosis of tumor tissue due to mechanical blockage of the tumor vasculature. The beads release cytotoxic oxaliplatin locally, which may result in oxaliplatin-mediated inhibition of tumor cell proliferation through formation of both inter- and intra-strand platinum-DNA crosslinks, and the inhibition of DNA replication.","text":"A formulation of drug-eluting beads (DEB) consisting of polymeric microbeads impregnated with the organoplatinum complex and alkylating agent oxaliplatin, with potential antineoplastic activity. The beads consist of polyvinyl alcohol (PVA) microspheres modified with sulfonic acid groups and loaded with oxaliplatin. During transarterial chemoembolization (TACE) in the hepatic artery, the oxaliplatin eluting beads occlude tumor blood vessels that feed the tumor and induce ischemic necrosis of tumor tissue due to mechanical blockage of the tumor vasculature. The beads release cytotoxic oxaliplatin locally, which may result in oxaliplatin-mediated inhibition of tumor cell proliferation through formation of both inter- and intra-strand platinum-DNA crosslinks, and the inhibition of DNA replication."},"drugInfoSummaryLink":null,"nciConceptId":"C172098","nciConceptName":"Oxaliplatin Eluting Beads","termId":801475,"name":"oxaliplatin eluting beads","firstLetter":"o","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"oxaliplatin-eluting-beads"},{"aliases":[{"type":"Abbreviation","name":"oxaliplatin-encapsulated Tf-conjugated NGPE liposome"},{"type":"CodeName","name":"MBP-426"}],"definition":{"html":"A nanoparticle formulation containing N-glutaryl phosphatidylethanolamine (NGPE)-liposomes encapsulating oxaliplatin and conjugated to the human transferrin (Tf) ligand, with potential antineoplastic activity. Upon infusion of oxaliplatin-encapsulated transferrin-conjugated NGPE liposomes, the transferrin moiety targets and binds to the Tf receptor, which is overexpressed on a variety of human cancer cells. Upon binding and internalization, oxaliplatin is released and its active derivatives alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, resulting in an inhibition of DNA replication and transcription. By extending the circulation time and specifically targeting transferrin receptors, this formulation may improve the efficacy and safety of oxaliplatin therapy, compared to administration of oxaliplatin alone. NGPE, a reactive phospholipid, is used as a linker to attach the Tf ligand, to the liposome.","text":"A nanoparticle formulation containing N-glutaryl phosphatidylethanolamine (NGPE)-liposomes encapsulating oxaliplatin and conjugated to the human transferrin (Tf) ligand, with potential antineoplastic activity. Upon infusion of oxaliplatin-encapsulated transferrin-conjugated NGPE liposomes, the transferrin moiety targets and binds to the Tf receptor, which is overexpressed on a variety of human cancer cells. Upon binding and internalization, oxaliplatin is released and its active derivatives alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, resulting in an inhibition of DNA replication and transcription. By extending the circulation time and specifically targeting transferrin receptors, this formulation may improve the efficacy and safety of oxaliplatin therapy, compared to administration of oxaliplatin alone. NGPE, a reactive phospholipid, is used as a linker to attach the Tf ligand, to the liposome."},"drugInfoSummaryLink":null,"nciConceptId":"C91074","nciConceptName":"Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome","termId":669661,"name":"oxaliplatin-encapsulated transferrin-conjugated N-glutaryl phosphatidylethanolamine liposome","firstLetter":"o","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":""}],"links":null}